BioSpace News Archive

Policy

FDA Finds Quality Control Problems at Moderna’s Vaccine Facility: Reuters

There is no evidence that the lapses have harmed patients who received Spikevax or clinical trial participants who received investigational shots.

December 18, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Bristol Myers Squibb Puts Kibosh on Trials of Colorectal Cancer Candidate

BMS will halt a trial investigating the Opdulag combination in colorectal cancer after determining that it would not hit its primary endpoint.

December 18, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Structure’s GLP-1 Drug Shows Efficacy in Phase IIa but Faces Stock Falloff

A GLP-1-based drug from Structure Therapeutics shows clinical promise but not enough for some on Wall Street.

December 18, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Point and Lantheus’s Radioligand Drug Shows Effectiveness, but Not Enough for Wall Street

While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.

December 18, 2023
·
2 min read
·
Tyler Patchen
In Second Fund, Pivotal Raises $389M to Create and Support Transformative Companies

The new fund brings Pivotal bioVenture Partners’ total capital to $689 million, which the venture capital firm intends to pump into young biotechs developing “innovative and impactful therapeutics.”

December 18, 2023
·
2 min read
·
Tristan Manalac
Policy

Illumina Loses Long Antitrust Battle, Readies to Divest GRAIL

Following a U.S. appeals court decision, the company said it is preparing to divest GRAIL through a third-party sale or capital markets transaction.

December 18, 2023
·
2 min read
·
Tristan Manalac
Business

Innate Pharma Announces Leadership Change - December 18, 2023

Innate Pharma SA announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company.

December 18, 2023
·
4 min read
Drug Development

IRLAB Submits Request for an End-of-Phase 2 Meeting with the FDA for the Phase III-ready Mesdopetam Program

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company has submitted a request for an end-of-Phase 2 meeting with the US FDA for the Phase III-ready mesdopetam program.

December 18, 2023
·
3 min read
Drug Development

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals announced the dosing of its first patient in its Phase 1 clinical trial of HFK1, a drug encapsulated immunoliposome containing doxorubicin for treatment of solid tumors.

December 18, 2023
·
3 min read
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference

Theravance Biopharma, Inc. today announced that members of its management team including Rick E Winningham, CEO, and Aziz Sawaf , CFO, will hold investor meetings during the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, in San Francisco, CA.

December 18, 2023
·
1 min read